Browse

You are looking at 11 - 20 of 1,482 items for

Shuqi Li Department of Endocrinology, Zhongshan Hospital, Fudan University, Shanghai, China

Search for other papers by Shuqi Li in
Google Scholar
PubMed
Close
,
Chenye Shi Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China

Search for other papers by Chenye Shi in
Google Scholar
PubMed
Close
,
Haifu Wu Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China

Search for other papers by Haifu Wu in
Google Scholar
PubMed
Close
,
Hongmei Yan Department of Endocrinology, Zhongshan Hospital, Fudan University, Shanghai, China

Search for other papers by Hongmei Yan in
Google Scholar
PubMed
Close
,
Mingfeng Xia Department of Endocrinology, Zhongshan Hospital, Fudan University, Shanghai, China

Search for other papers by Mingfeng Xia in
Google Scholar
PubMed
Close
,
Heng Jiao Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China

Search for other papers by Heng Jiao in
Google Scholar
PubMed
Close
,
Yang He Department of Endocrinology, Zhongshan Hospital, Fudan University, Shanghai, China

Search for other papers by Yang He in
Google Scholar
PubMed
Close
,
Ming Zhong Department of Critical Care Medicine, Zhongshan Hospital, Fudan University, Shanghai, China

Search for other papers by Ming Zhong in
Google Scholar
PubMed
Close
,
Wenhui Lou Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China

Search for other papers by Wenhui Lou in
Google Scholar
PubMed
Close
,
Xin Gao Department of Endocrinology, Zhongshan Hospital, Fudan University, Shanghai, China

Search for other papers by Xin Gao in
Google Scholar
PubMed
Close
,
Hua Bian Department of Endocrinology, Zhongshan Hospital, Fudan University, Shanghai, China

Search for other papers by Hua Bian in
Google Scholar
PubMed
Close
, and
Xinxia Chang Department of Endocrinology, Zhongshan Hospital, Fudan University, Shanghai, China

Search for other papers by Xinxia Chang in
Google Scholar
PubMed
Close

Background

Bariatric surgery induces significant weight loss, increases insulin sensitivity, and improves dyslipidemia. As one of the most widely performed bariatric surgeries, laparoscopic sleeve gastrectomy (LSG) is thought to improve the metabolic profile along with weight loss. The objective of this study was to evaluate longitudinal changes in the serum metabolite levels after LSG and elucidate the underlying mechanisms of metabolic improvement.

Methods

Clinical metabolic parameters and serum samples were collected preoperatively and at 1, 3, and 6 months postoperatively from nine patients with obesity undergoing LSG. Serum metabolites were measured using a non-targeted metabolic liquid chromatography–mass spectrometry method.

Results

During the 1, 3, and 6 months postoperative follow-up, the body mass index, HOMA-IR, and liver fat content showed a gradual descending trend. A total of 328 serum metabolites were detected, and 38 were differentially expressed. The up-regulated metabolites were mainly enriched in ketone body metabolism, alpha-linolenic acid and linoleic acid metabolism, pantothenate and CoA biosynthesis, glycerolipid metabolism, and fructose and mannose degradation, while the down-regulated metabolites were closely related to caffeine metabolism, oxidation of branched-chain fatty acids, glutamate metabolism, and homocysteine degradation. Notably, nine metabolites (oxoglutarate, 2-ketobutyric acid, succinic acid semialdehyde, phthalic acid, pantetheine, eicosapentaenoate, 3-hydroxybutanoate, oxamic acid, and dihydroxyfumarate) showed persistent differential expression at 1, 3, and 6 months follow-up. Some were found to be significantly associated with weight loss, insulin resistance improvement, and liver fat content reduction.

Conclusions

This finding may provide a new perspective for revealing novel biomarkers and mechanisms of metabolic improvement in obesity and related comorbidities.

Open access
Xu-Feng Chen Department of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai, People’s Republic of China
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of China

Search for other papers by Xu-Feng Chen in
Google Scholar
PubMed
Close
,
Cong He Department of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai, People’s Republic of China
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of China

Search for other papers by Cong He in
Google Scholar
PubMed
Close
,
Peng-Cheng Yu Department of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai, People’s Republic of China
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of China

Search for other papers by Peng-Cheng Yu in
Google Scholar
PubMed
Close
,
Wei-Dong Ye Department of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai, People’s Republic of China
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of China

Search for other papers by Wei-Dong Ye in
Google Scholar
PubMed
Close
,
Pei-Zheng Han Department of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai, People’s Republic of China
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of China

Search for other papers by Pei-Zheng Han in
Google Scholar
PubMed
Close
,
Jia-Qian Hu Department of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai, People’s Republic of China
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of China

Search for other papers by Jia-Qian Hu in
Google Scholar
PubMed
Close
, and
Yu-Long Wang Department of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai, People’s Republic of China
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of China

Search for other papers by Yu-Long Wang in
Google Scholar
PubMed
Close

Next-generation sequencing (NGS) is of great benefit to clinical practice in terms of identifying genetic alterations. This study aims to clarify the gene background and its influence on thyroid tumors in the Chinese population. NGS data and corresponding clinicopathological features (sex, age, tumor size, extrathyroidal invasion, metastasis, multifocality, and TNM stage) were collected and analyzed retrospectively from 2844 individual thyroid tumor samples from July 2021 to August 2022. Among the cohort, 2337 (82%) cases possess genetic alterations, including BRAF (71%), RAS (4%), RET/PTC (4%), TERT (3%), RET (2.2%), and TP53 (1.4%). Diagnostic sensitivity before surgery can be significantly increased from 0.76 to 0.91 when cytology is supplemented by NGS. Our results show that BRAF-positive papillary thyroid cancer (PTC) patients tend to have older age, smaller tumor size, less vascular invasion, more frequent tumor multifocality, and a significantly higher cervical lymph node metastatic rate. Mutation at RET gene codons 918 and 634 is strongly correlated with medullary thyroid cancer. However, it did not display more invasive clinical characteristics. TERT-positive patients are more likely to have older age, and have larger tumor size, more tumor invasiveness, and more advanced TNM stage, indicating a poor prognosis. Patients with TERT, RET/PTC1, and CHEK2 mutations are more susceptible to lateral lymph node metastasis. In conclusion, NGS can be a useful tool that provides practical gene evidence in the process of diagnosis and treatment in thyroid tumors.

Open access
Ayanthi Wijewardene Department of Endocrinology, Royal North Shore Hospital, Sydney, Australia
Faculty of Medicine, The University of Sydney, Sydney, Australia

Search for other papers by Ayanthi Wijewardene in
Google Scholar
PubMed
Close
,
Matti Gild Department of Endocrinology, Royal North Shore Hospital, Sydney, Australia
Faculty of Medicine, The University of Sydney, Sydney, Australia

Search for other papers by Matti Gild in
Google Scholar
PubMed
Close
,
Lyndal Tacon Department of Endocrinology, Royal North Shore Hospital, Sydney, Australia
Faculty of Medicine, The University of Sydney, Sydney, Australia

Search for other papers by Lyndal Tacon in
Google Scholar
PubMed
Close
,
Venessa Tsang Department of Endocrinology, Royal North Shore Hospital, Sydney, Australia
Faculty of Medicine, The University of Sydney, Sydney, Australia

Search for other papers by Venessa Tsang in
Google Scholar
PubMed
Close
,
Anthony J Gill Faculty of Medicine, The University of Sydney, Sydney, Australia
Department of Anatomical Pathology, NSW Health Pathology, Royal North Shore Hospital, Sydney, Australia
Cancer Diagnosis and Pathology Group, Kolling Institute of Medical Research, Royal North Shore Hospital, Sydney Australia

Search for other papers by Anthony J Gill in
Google Scholar
PubMed
Close
,
Anthony Robert Glover Faculty of Medicine, The University of Sydney, Sydney, Australia
Department of Endocrine Surgery, Royal North Shore Hospital, Sydney, Australia

Search for other papers by Anthony Robert Glover in
Google Scholar
PubMed
Close
,
Mark Sywak Faculty of Medicine, The University of Sydney, Sydney, Australia
Department of Endocrine Surgery, Royal North Shore Hospital, Sydney, Australia

Search for other papers by Mark Sywak in
Google Scholar
PubMed
Close
,
Stan Sidhu Faculty of Medicine, The University of Sydney, Sydney, Australia
Department of Endocrine Surgery, Royal North Shore Hospital, Sydney, Australia

Search for other papers by Stan Sidhu in
Google Scholar
PubMed
Close
,
Bruce Robinson Department of Endocrinology, Royal North Shore Hospital, Sydney, Australia
Faculty of Medicine, The University of Sydney, Sydney, Australia

Search for other papers by Bruce Robinson in
Google Scholar
PubMed
Close
,
Paul Roach Faculty of Medicine, The University of Sydney, Sydney, Australia
Department of Nuclear Medicine, Royal North Shore Hospital, Sydney, Australia

Search for other papers by Paul Roach in
Google Scholar
PubMed
Close
,
Geoffrey Schembri Faculty of Medicine, The University of Sydney, Sydney, Australia
Department of Nuclear Medicine, Royal North Shore Hospital, Sydney, Australia

Search for other papers by Geoffrey Schembri in
Google Scholar
PubMed
Close
,
Jeremy Hoang Faculty of Medicine, The University of Sydney, Sydney, Australia
Department of Nuclear Medicine, Royal North Shore Hospital, Sydney, Australia

Search for other papers by Jeremy Hoang in
Google Scholar
PubMed
Close
, and
Roderick Clifton-Bligh Department of Endocrinology, Royal North Shore Hospital, Sydney, Australia
Faculty of Medicine, The University of Sydney, Sydney, Australia

Search for other papers by Roderick Clifton-Bligh in
Google Scholar
PubMed
Close

Summary

Background

Noise, an unwanted variability in judgment, is ubiquitous in medicine, including in the prescription of radioactive iodine (RAI). Building upon our recently developed predictive risk model, we created an online clinical support tool to facilitate the translation of our model into clinical practice. The aim of this study is to assess the utility of an online clinical support tool to reduce noise in the treatment for patients with differentiated thyroid cancer (DTC).

Methods

The tool was accessible via weblink or a QR code. Activity recommendations were applied to the calculator’s four risk categories: 0 GBq for very low risk, 1 GBq for low risk, 4 GBq for intermediate risk, and 6 GBq for high risk. The tool was applied prospectively to 103 patients who received RAI at Royal North Shore Hospital between 2021 and 2022 and retrospectively to 393 patients treated with RAI between 2017 and 2021.

Results

A significant difference was observed in administered activity between the 2021–2022 and 2017–2021 cohorts in patients stratified as intermediate risk (median activity 3.95 GBq, interquartile range 2.03–4.04 vs 4 GBq, 4–4) and high risk (4.07 GBq, 3.95–5.7 vs 6 GBq, 6–6) with P-values of 0.01 and <0.01, respectively. No difference was seen in low-risk patients (2.01 GBq, 1.03–3.98 vs 1 GBq, 1–4, P = 0.30). Additionally, no clinically significant recurrence was observed between the two cohorts (6.6% vs 4.5%; P = 0.628).

Conclusion

Optimal risk classification and activity recommendation continue to be established. Our data suggest that providing risk stratification and activity recommendation in an easy-to-access online tool can reduce noise and variability in activity prescription for patients with DTC.

Open access
Zeting Li Department of Endocrinology, Sun Yat-sen University First Affiliated Hospital, Guangzhou, China

Search for other papers by Zeting Li in
Google Scholar
PubMed
Close
,
Ling Pei Department of Endocrinology, Sun Yat-sen University First Affiliated Hospital, Guangzhou, China

Search for other papers by Ling Pei in
Google Scholar
PubMed
Close
,
Huangmeng Xiao Department of Endocrinology, Sun Yat-sen University First Affiliated Hospital, Guangzhou, China

Search for other papers by Huangmeng Xiao in
Google Scholar
PubMed
Close
,
Nan Chen Department of Endocrinology, Sun Yat-sen University First Affiliated Hospital, Guangzhou, China

Search for other papers by Nan Chen in
Google Scholar
PubMed
Close
,
Fenghua Lai Department of Endocrinology, Sun Yat-sen University First Affiliated Hospital, Guangzhou, China

Search for other papers by Fenghua Lai in
Google Scholar
PubMed
Close
,
Shufang Yue Department of Endocrinology, Sun Yat-sen University First Affiliated Hospital, Guangzhou, China

Search for other papers by Shufang Yue in
Google Scholar
PubMed
Close
,
Changliu Xu Department of Endocrinology, Sun Yat-sen University First Affiliated Hospital, Guangzhou, China

Search for other papers by Changliu Xu in
Google Scholar
PubMed
Close
,
Yanbing Li Department of Endocrinology, Sun Yat-sen University First Affiliated Hospital, Guangzhou, China

Search for other papers by Yanbing Li in
Google Scholar
PubMed
Close
,
Haipeng Xiao Department of Endocrinology, Sun Yat-sen University First Affiliated Hospital, Guangzhou, China

Search for other papers by Haipeng Xiao in
Google Scholar
PubMed
Close
, and
Xiaopei Cao Department of Endocrinology, Sun Yat-sen University First Affiliated Hospital, Guangzhou, China

Search for other papers by Xiaopei Cao in
Google Scholar
PubMed
Close

Glucose-like peptide-1 (GLP-1) is a vital hormone in the intestines that regulates glucose metabolism. Although pancreatic-derived factor (PANDER) overexpression is known to suppress GLP-1, the underlying mechanisms are unclear. Our study aims to uncover how PANDER influences GLP-1 synthesis and secretion. We established a PANDER overexpression model in STC-1 intestinal cells, confirming its inhibitory effect on GLP-1 secretion. This effect was reversed in PANDER-knockout cells. Additionally, a negative correlation between PANDER and GLP-1 was observed in patients with a history of gestational diabetes. Subsequently, through whole transcriptome gene sequencing in PANDER-overexpressed STC-1 cells, we discovered that the activation of IL-6 and its related STAT3 signaling pathway was significantly inhibited, and this finding was validated by Western blotting and quantitative reverse transcription PCR. Finally, rescue experiments confirmed that the IL-6-related STAT3/Akt/GSK3β/β-catenin signaling pathway mediates the negative regulatory effect of PANDER on GLP-1. Taken together, our data identify IL-6 as a bridge connecting PANDER and GLP-1 in the STC-1 cells, demonstrating potential therapeutic targets for diabetes treatment by targeting the PANDER–IL-6–GLP-1 axis.

Open access
Tianze Ding T Ding, Department of Clinical Nutrition, College of Health Science and Technology, Shanghai Jiao Tong University School of Medicine, Shanghai, China

Search for other papers by Tianze Ding in
Google Scholar
PubMed
Close
,
Peijie Liu P Liu, Department of Clinical Nutrition, College of Health Science and Technology, Shanghai Jiao Tong University School of Medicine, Shanghai, China

Search for other papers by Peijie Liu in
Google Scholar
PubMed
Close
,
Jie Jia J Jia, Department of Clinical Nutrition, College of Health Science and Technology, Shanghai Jiao Tong University School of Medicine, Shanghai, China

Search for other papers by Jie Jia in
Google Scholar
PubMed
Close
,
Hui Wu H Wu, Department of Nutrition, Seventh People’s Hospital of shanghai University of Traditional Chinese Medicine, Shanghai, China

Search for other papers by Hui Wu in
Google Scholar
PubMed
Close
,
Jie Zhu J Zhu, Nutrition and Foods Program, School of Family and Consumer Sciences, Texas State University, San Marcos, United States

Search for other papers by Jie Zhu in
Google Scholar
PubMed
Close
, and
Kefeng Yang K Yang, Department of Clinical Nutrition, College of Health Science and Technology, Shanghai Jiao Tong University School of Medicine, Shanghai, China

Search for other papers by Kefeng Yang in
Google Scholar
PubMed
Close

Introduction: Gestational diabetes mellitus (GDM) significantly affects pregnancy outcomes. Therefore, it is crucial to develop prediction models since they can guide timely interventions to reduce the incidence of GDM and its associated adverse effects.

Methods: A total of 554 pregnant women were selected and their sociodemographic characteristics, clinical data and dietary data were collected. Dietary data was investigated by a validated semi-quantitative food frequency questionnaire (FFQ). We applied random forest mean decrease impurity for feature selection and the models are built using Logistic Regression, XGBoost, and LightGBM algorithms. The prediction performance of different models was compared by Accuracy, Sensitivity, Specificity, Area Under Curve (AUC) and Hosmer-Lemeshow test.

Results: Blood glucose, age, pre-pregnancy body mass index (BMI), triglycerides and high-density lipoprotein cholesterol (HDL) were the top five features according to the feature selection. Among the three algorithms, XGBoost performed best with an AUC of 0.788, LightGBM came second (AUC = 0.749), and Logistic Regression performed the worst (AUC = 0.712). In addition, XGBoost and LightGBM both achieved a fairly good performance when dietary information was included, surpassing their performance on the non-dietary dataset (0.788 vs. 0.718 in XGBoost; 0.749 vs. 0.726 in LightGBM).

Conclusion: XGBoost and LightGBM algorithms outperform Logistic Regression in predicting GDM among the Chinese pregnant women. In addition, dietary data may have a positive effect on improving model performance, which deserves more in-depth investigation with larger sample size.

Open access
Yankun Liang Y Liang, Jinan University, Guangzhou, China

Search for other papers by Yankun Liang in
Google Scholar
PubMed
Close
,
Zhenpo Zhang Z Zhang, Jinan University, Guangzhou, China

Search for other papers by Zhenpo Zhang in
Google Scholar
PubMed
Close
,
Jingping Zheng J Zheng, Jinan University, Guangzhou, China

Search for other papers by Jingping Zheng in
Google Scholar
PubMed
Close
,
Yuting Wang Y Wang, Jinan University, Guangzhou, United States

Search for other papers by Yuting Wang in
Google Scholar
PubMed
Close
,
Jiaxin He J He, Guangdong Food and Drug Vocational College, Guangzhou, China

Search for other papers by Jiaxin He in
Google Scholar
PubMed
Close
,
Juanzhi Zhao J Zhao, Department of Pharmacy, Sun Yat-Sen University, Guangzhou, 510275, China

Search for other papers by Juanzhi Zhao in
Google Scholar
PubMed
Close
, and
Ling Su L Su, Jinan University, Guangzhou, 510632, China

Search for other papers by Ling Su in
Google Scholar
PubMed
Close

Aim: Incretin therapies, including dipeptidyl peptidase-4 inhibitors (DPP-4is) and glucagon-like peptide-1 receptor agonists (GLP-1RAs), are crucial for type 2 diabetes treatment. Evidence on their association with gallbladder, biliary diseases and liver injury remains inconsistent. This study evaluated the association between incretin therapies and hepatobiliary adverse events using FDA's Adverse Event Reporting System (FAERS) data.

Methods: Case reports involving incretin therapies and hepatobiliary events from January 2006 to December 2023 were extracted from FAERS. The association between these agents and hepatobiliary adverse events (hAEs) was analyzed using reporting odds ratios and empirical Bayesian geometric means. Descriptive analyses were conducted to characterize the demographic and clinical features of the hAE cases. Additionally, subgroup analyses calculated reporting odds ratios to evaluate the strength of association between specific incretin drugs and hAEs.

Results: Among 68,351 case reports associated with incretin-based therapies, 1,327 (1.941%) involved hepatobiliary adverse events. DPP-4 inhibitors demonstrated statistically significant associations with multiple hepatobiliary events like cholelithiasis, cholecystitis chronic, and biliary diseases. In contrast, GLP-1 receptor agonists showed weaker associations, primarily linked to gallbladder and biliary disease risks. Subgroup analyses revealed stronger positive correlations with hepatobiliary events for liraglutide and semaglutide among GLP-1 agonists, and for sitagliptin, linagliptin, and vildagliptin among DPP-4 inhibitors. The pooled reporting odds ratio of 2.85 indicated a positive correlation between these drugs and studied adverse events.

Conclusions: This study found statistically significant associations between DPP-4 inhibitors and hepatobiliary adverse events like cholelithiasis and cholecystitis. GLP-1 agonists showed weaker gallbladder/biliary disorder links but higher acute cholecystitis risk. Subgroup analyses revealed varying correlations among specific drugs, potentially dose-dependent. Further large-scale studies are needed to evaluate class effect differences and elucidate mechanisms for guiding clinical use.

Open access
Demi T.c. de Winter D de Winter, Princess Máxima Center for Pediatric Oncology, Prinses Maxima Centrum voor Kinderoncologie BV, Utrecht, Netherlands

Search for other papers by Demi T.c. de Winter in
Google Scholar
PubMed
Close
,
Sebastian J.c.m.m. Neggers S Neggers, Department of Internal Medicine, section Endocrinology, Erasmus MC University Medical Center Rotterdam, Rotterdam, Netherlands

Search for other papers by Sebastian J.c.m.m. Neggers in
Google Scholar
PubMed
Close
,
Mm van den Heuvel-Eibrink M van den Heuvel-Eibrink, Princess Máxima Center for Pediatric Oncology, Prinses Maxima Centrum voor Kinderoncologie BV, Utrecht, Netherlands

Search for other papers by Mm van den Heuvel-Eibrink in
Google Scholar
PubMed
Close
, and
Jenneke E. van Atteveld J van Atteveld, Princess Máxima Center for Pediatric Oncology, Prinses Maxima Centrum voor Kinderoncologie BV, Utrecht, Netherlands

Search for other papers by Jenneke E. van Atteveld in
Google Scholar
PubMed
Close

Childhood cancer survivors are at increased risk of developing (long-term) skeletal adverse effects, such as osteonecrosis, impaired bone mineral density, and fractures. This paper provides an overview of the current understanding of bone health in these survivors, examining whether it represents a significant concern. It focuses on the challenges of assessing and managing bone health in childhood cancer survivors, highlighting diagnostic pitfalls, methods for accurately identifying those at high risk, and suggested strategies for surveillance and management of osteonecrosis and impaired bone mineral density. The need for improved surveillance strategies, particularly for high-risk survivors, alongside potential prevention and management options, including pharmacological and lifestyle interventions, is emphasised. Given the lack of consensus on optimal prevention and treatment strategies, the paper emphasises the need for further research to optimise care and improve long-term outcomes for childhood cancer survivors with bone health impairments.

Open access
I M A A van Roessel Department of Pediatric Neuro-oncology, Princess Máxima Center, Heidelberglaan, CS Utrecht, The Netherlands
Department of Pediatric Endocrinology, Wilhelmina Children’s Hospital, University Medical Center, Lundlaan, EA Utrecht, The Netherlands

Search for other papers by I M A A van Roessel in
Google Scholar
PubMed
Close
,
J E Gorter Department of Pediatric Neuro-oncology, Princess Máxima Center, Heidelberglaan, CS Utrecht, The Netherlands
Department of Pediatric Endocrinology, Wilhelmina Children’s Hospital, University Medical Center, Lundlaan, EA Utrecht, The Netherlands

Search for other papers by J E Gorter in
Google Scholar
PubMed
Close
,
B Bakker Department of Pediatric Neuro-oncology, Princess Máxima Center, Heidelberglaan, CS Utrecht, The Netherlands
Department of Pediatric Endocrinology, Wilhelmina Children’s Hospital, University Medical Center, Lundlaan, EA Utrecht, The Netherlands

Search for other papers by B Bakker in
Google Scholar
PubMed
Close
,
M M van den Heuvel-Eibrink Princess Máxima Center, Heidelberglaan, CS Utrecht, The Netherlands
Wilhelmina Children’s Hospital, University Medical Center, Lundlaan, EA Utrecht, The Netherlands

Search for other papers by M M van den Heuvel-Eibrink in
Google Scholar
PubMed
Close
,
M H Lequin Department of Radiology, Princess Máxima Center, Heidelberglaan, CS Utrecht, The Netherlands
Department of Radiology, Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht, The Netherlands

Search for other papers by M H Lequin in
Google Scholar
PubMed
Close
,
J van der Lugt Department of Pediatric Neuro-oncology, Princess Máxima Center, Heidelberglaan, CS Utrecht, The Netherlands

Search for other papers by J van der Lugt in
Google Scholar
PubMed
Close
,
L Meijer Department of Pediatric Neuro-oncology, Princess Máxima Center, Heidelberglaan, CS Utrecht, The Netherlands

Search for other papers by L Meijer in
Google Scholar
PubMed
Close
,
A Y N Schouten-van Meeteren Department of Pediatric Neuro-oncology, Princess Máxima Center, Heidelberglaan, CS Utrecht, The Netherlands

Search for other papers by A Y N Schouten-van Meeteren in
Google Scholar
PubMed
Close
, and
H M van Santen Department of Pediatric Neuro-oncology, Princess Máxima Center, Heidelberglaan, CS Utrecht, The Netherlands
Department of Pediatric Endocrinology, Wilhelmina Children’s Hospital, University Medical Center, Lundlaan, EA Utrecht, The Netherlands

Search for other papers by H M van Santen in
Google Scholar
PubMed
Close

Objective

Children with a supratentorial midline low-grade glioma (LGG) may be at risk for impaired bone health due to hypothalamic-pituitary dysfunction, obesity, exposure to multiple treatment modalities, and/or decreased mobility. The presence of impaired bone health and/or its severity in this population has been understudied. We aimed to identify the prevalence and risk factors for bone problems in children with supratentorial midline LGG.

Materials and methods

A retrospective study was performed in children with supratentorial midline (suprasellar or thalamic) LGG between 1 January 2003 and 1 January 2022, visiting the Princess Máxima Center for Pediatric Oncology. Impaired bone health was defined as the presence of vertebral fractures and/or very low bone mineral density (BMD).

Results

In total, 161 children were included, with a median age at tumor diagnosis of 4.7 years (range: 0.1–17.9) and a median follow-up of 6.1 years (range: 0.1–19.9). Five patients (3.1%) had vertebral fractures. In 99 patients, BMD was assessed either by Dual Energy X-ray Absorptiometry (n = 12) or Bone Health Index (n = 95); 34 patients (34.3%) had a low BMD (≤ −2.0). Impaired visual capacity was associated with bone problems in multivariable analysis (OR: 6.63, 95% CI: 1.83–24.00, P = 0.004).

Conclusion

In this retrospective evaluation, decreased BMD was prevalent in 34.3% of children with supratentorial midline LGG. For the risk of developing bone problems, visual capacity seems highly relevant. Surveillance of bone health must be an aspect of awareness in the care and follow-up of children with a supratentorial midline LGG.

Significance statement

Patients with supratentorial midline LGG may encounter various risk factors for impaired bone health. Bone problems in survivors of childhood supratentorial midline LGG are, however, understudied. This is the first paper to address the prevalence of bone problems in this specific patient population, revealing visual problems as an important risk factor. Diencephalic syndrome historyand/or weight problems associated with hypothalamic dysfunction were related to bone problems in univariate analyses. The results of this study can be used in the development of guidelines to adequately screen and treat these patients to subsequently minimizing bone problems as one of the endocrine complications.

Open access
Yanaika S Sabogal Pineros Y Sabogal Pineros, Laboratory Medicine, Endocrine Laboratory, Amsterdam UMC Locatie AMC, Amsterdam, Netherlands

Search for other papers by Yanaika S Sabogal Pineros in
Google Scholar
PubMed
Close
,
Martine M.L. Deckers M Deckers, Clinical Chemistry, OLVG, Amsterdam, Netherlands

Search for other papers by Martine M.L. Deckers in
Google Scholar
PubMed
Close
,
Prim de Bie P de Bie, Clinical Chemistry, OLVG, Amsterdam, Netherlands

Search for other papers by Prim de Bie in
Google Scholar
PubMed
Close
,
Annemieke C Heijboer A Heijboer , Laboratory Medicine, Endocrine Laboratory, Amsterdam UMC Locatie AMC, Amsterdam, Netherlands

Search for other papers by Annemieke C Heijboer in
Google Scholar
PubMed
Close
, and
Jacquelien J. Hillebrand J Hillebrand, Endocrine Laboratory, Department of Clinical Chemistry, Amsterdam UMC Locatie AMC, Amsterdam, Netherlands

Search for other papers by Jacquelien J. Hillebrand in
Google Scholar
PubMed
Close

Objective. Serum prolactin measurements are important in the differential diagnosis of pituitary masses and subfertility. We observed discrepancies in serum prolactin levels in several patients measured with different immunoassays. Despite differences in assay results, the reference intervals derived by the manufacturers were similar. In this study we aimed to investigate prolactin assay differences and to re-establish RIs for different prolactin immunoassays.

Methods. For the assay comparison, serum samples were collected from men and women visiting our the Amsterdam UMC hospital. Prolactin levels were measured using the AtellicaTM IM analyzer (Siemens Healthineers) and the Cobas (Roche Diagnostics) immunoassay. Reference intervals for prolactin were re-established for men, premenopausal women and postmenopausal women for both the Atellica and Cobas immunoassay.

Results. Prolactin levels measured using the Cobas immunoassay were 1.75 times higher than those measured using the Atellica immunoassay. The re-established reference intervals for Atellica and Cobas confirmed these findings and were <0.32 U/L; <0.55 U/L for men; <0.64 U/L; <0.86 U/L for premenopausal women and <0.31 U/L; <0.59 U/L for postmenopausal women, respectively for Atellica and Cobas assays. The re-established RIs of the Atellica assay matched the current and manufacturer RIs whereas those for Cobas differed substantially.

Conclusions. Prolactin levels are assay dependent and the re-established reference intervals are different for the Atellica and Cobas assays. We recommend that laboratory specialists and manufacturers periodically review prolactin assay RIs as incorrect reference intervals can lead to misinterpretation of prolactin levels and unnecessary referrals and further laboratory testing, as we have experienced.

Open access
Muyang He M He, Department of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, 200032, China

Search for other papers by Muyang He in
Google Scholar
PubMed
Close
,
Haijia Xu H Xu, Endocrinology and Metabolism, Zhongshan Hospital Fudan University, Shanghai, China

Search for other papers by Haijia Xu in
Google Scholar
PubMed
Close
,
Zhen Ying Z Ying, Endocrinology and Metabolism, Zhongshan Hospital Fudan University, Shanghai, China

Search for other papers by Zhen Ying in
Google Scholar
PubMed
Close
,
Chen Ying C Ying, Shanghai, United Kingdom of Great Britain and Northern Ireland

Search for other papers by Chen Ying in
Google Scholar
PubMed
Close
, and
Xiaoying Li X Li, Department of Endocrinology, Fudan University Shanghai, Shanghai, 200032, China

Search for other papers by Xiaoying Li in
Google Scholar
PubMed
Close

Acquired hypothalamic obesity (HO) is a rare type of obesity caused by acquired disease-related and/or treatment-related damage to the hypothalamus, most commonly craniopharyngiomas. Effective management of HO is critical due to its significant impact on quality of life and resistance to conventional treatments. This systematic review and meta-analysis aims to evaluate the 12-month, 24-month and 60-month outcomes of bariatric surgery for HO caused by CPs compared with patients with common obesity (CO). Relevant studies were identified in MEDLINE and EMBASE databases until May 2024. A total of 4 matched case-control studies were included. The results indicated that bariatric surgery significantly reduced weight in patients with hypothalamic obesity (22.98±14.22/21.47 ± 9.61/19.07±16.12 %total weight loss, 12/24/60 months after surgery) but the effect was significantly less than in common obesity controls (-6.17/-6.41/-7.72 %total weight loss 12/24/60 months after surgery). Bariatric surgery can significantly reduce body weight in craniopharyngiomas-related hypothalamic obesity, but the effect is less than in matched patients with common obesity. Further studies are necessary to determine the best surgical or multidisciplinary approach to the treatment of acquired hypothalamic obesity.

Open access